Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential cisplatin/paclitaxel followed by tislelizumab as neoadjuvant therapy for locally advanced cervical cancer
ChiCTR2400081548Phase 2Recruiting
- Sponsor
- Jiangmen Central Hospital
- Start
- Mar 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cisplatin, paclitaxel and tislelizumab in Cervical Cancer (CC), sponsored by Jiangmen Central Hospital. Primary endpoint: Pathological complete response rate. Started Mar 2024; status: recruiting.
02
Drugs
cisplatinpaclitaxeltislelizumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2400081548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081548.